Combined chelation with high-dose deferiprone and deferoxamine to improve survival and restore cardiac function effectively in patients with transfusion-dependent thalassemia presenting severe cardiac complications-Reference-Cited by-同舟云学术

Combined chelation with high-dose deferiprone and deferoxamine to improve survival and restore cardiac function effectively in patients with transfusion-dependent thalassemia presenting severe cardiac complications

Published:2020-07-31 Issue:10 Volume:99 Page:2289-2294
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Chuang Tzu-Yao,Li Ju-Pi,Weng Te-Fu,Wu Kang-Hsi,Chao Yu-Hua^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00277-020-04196-y.pdf

Reference26 articles.

1. Pennell DJ, Udelson JE, Arai AE, Bozkurt B, Cohen AR, Galanello R, Hoffman TM, Kiernan MS, Lerakis S, Piga A, Porter JB, Walker JM, Wood J (2013) Cardiovascular function and treatment in beta-thalassemia major: a consensus statement from the American Heart Association. Circulation 128(3):281–308

2. Hershko C (2010) Pathogenesis and management of iron toxicity in thalassemia. Ann N Y Acad Sci 1202:1–9

3. Pennell DJ (2005) T2* magnetic resonance and myocardial iron in thalassemia. Ann N Y Acad Sci 1054:373–378

4. Jessup M, Manno CS (1998) Diagnosis and management of iron-induced heart disease in Cooley’s anemia. Ann N Y Acad Sci 850:242–250

5. Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, Gotsis ED, Tanner MA, Smith GC, Westwood MA, Wonke B, Galanello R (2006) Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 107(9):3738–3744

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diagnostic et traitement d’une surcharge en fer;La Revue de Médecine Interne;2023-12

2. Drug Selection and Posology, Optimal Therapies and Risk/Benefit Assessment in Medicine: The Paradigm of Iron-Chelating Drugs;International Journal of Molecular Sciences;2023-11-25

3. The Vital Role Played by Deferiprone in the Transition of Thalassaemia from a Fatal to a Chronic Disease and Challenges in Its Repurposing for Use in Non-Iron-Loaded Diseases;Pharmaceuticals;2023-07-18

4. Ebselen: A promising therapy protecting cardiomyocytes from excess iron in iron-overloaded thalassemia patients;Open Medicine;2023-01-01

5. Diagnostic et traitement d’une surcharge en fer;La Revue de Médecine Interne;2022-12